New allergy drug AK139 enters human testing for spring misery
NCT ID NCT07436234
First seen Mar 02, 2026 · Last updated May 23, 2026 · Updated 9 times
Summary
This study tests a new medicine called AK139 for people with moderate to severe seasonal allergic rhinitis (hay fever). About 111 adults aged 18 to 65 with at least a 2-year history of seasonal allergies will receive either AK139 or a placebo. The main goal is to see if AK139 reduces daily nasal symptoms like stuffiness and sneezing over 2 weeks, and to check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEASONAL ALLERGIC RHINITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tong-Ren hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.